Pharma announces extra data from APF530 Phase 3 study on CINV A.

Pharma, Inc. , a specialty pharmaceutical firm, today announced additional data from the Company’s Phase 3 study of APF530 for the prevention of chemotherapy-induced nausea and vomiting . The ongoing organization presented the study outcomes today at a poster demonstration during the Multinational Association of Supportive Treatment in Tumor and the International Culture of Oral Oncology International Symposium in NY. As reported previously, the Phase 3 research showed APF530 was comparable to palonosetron in preventing both acute – and delayed-onset CINV in patients getting either moderately emetogenic chemotherapy or extremely emetogenic chemotherapy .Dr. Kapoor emphasized AICC’s commitment to working with legislators and regulators on the state and national levels to curb over-utilization of healthcare services while preserving patient usage of comprehensive cancer care in the multi-specialty physician group practice setting.

3SBio announces Nephoxil collaboration and license agreement with Panacor Bioscience 3SBio Inc. , a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced a collaboration and permit agreement with Panacor Bioscience Ltd today. To develop and commercialize its Nephoxil pharmaceutical item for the treatment of hyperphosphatemia in China.